Key Highlights
- Loss per share was USD 0.20 against an estimate of a USD 0.14 loss.
- Government contract Revenue was USD 105 thousand.
- Net loss was USD 3.44 million, compared with USD 2.05 million.
- Cash was USD 4.87 million at September 30, 2026.
Cocrystal Pharma (NASDAQ:COCP) reported a net loss of USD 3.44 million for the third quarter of 2026, compared with USD 2.05 million in the prior-year quarter. Net loss per common share, basic and diluted, was USD 0.20, compared with USD 0.19, against an estimate of a USD 0.14 loss.
The company recognized government contract revenue of USD 105 thousand for the quarter and USD 435 thousand for the nine months ended September 30, 2026. The filing states that the contract is with NIAID, which is the customer for Research and Development services.
Operating Expenses
Research and development expenses were USD 1.98 million, compared with USD 954 thousand, and general and administrative expenses were USD 1.62 million, compared with USD 1.14 million. Total operating expenses were USD 3.59 million, compared with USD 2.09 million, and the loss from operations was USD 3.49 million, compared with USD 2.09 million.
Total other income, net, was USD 45 thousand, compared with USD 40 thousand, including net interest income of USD 15 thousand and a foreign exchange gain of USD 30 thousand. Weighted average shares outstanding were 17,419 thousand, compared with 10,991 thousand.
Nine-Month Results
For the nine months, research and development expenses were USD 5.49 million, compared with USD 3.44 million, and general and administrative expenses were USD 3.97 million, compared with USD 3.10 million. Total operating expenses were USD 9.46 million, compared with USD 6.54 million.
The loss from operations was USD 9.03 million, compared with USD 6.54 million. The net loss was USD 8.91 million, compared with USD 6.41 million, and net loss per common share was USD 0.59, compared with USD 0.61.
Cash and Liquidity
Cash was USD 4.87 million at September 30, 2026, compared with USD 7.03 million at December 31, 2025, and restricted cash was USD 75 thousand. A government contract receivable of USD 35 thousand was recorded at September 30, 2026.
The filing states that the company believes its current resources are not sufficient to fund operations for at least the next 12 months from the date the financial statements are issued. The filing also states that the company sold and issued 5,474,053 shares of common stock to an Accredited Investor at a purchase price of USD 0.9134 per share, for gross proceeds of USD 5.0 million. The filing reports approximately 19,264,893 shares outstanding as of November 16, 2026.
The filing states that the company has identified preclinical and clinical-stage antiviral compounds for unmet medical needs caused by RNA viruses, including norovirus, influenza virus, coronaviruses and hepatitis C virus. During the nine months ended September 30, 2026, the company continued to focus its research and development efforts primarily on norovirus, influenza and coronavirus. The filing also states that the company engaged hVIVO Services Ltd., a United Kingdom clinical research organization, to conduct its Phase 2a human challenge study of oral CC-42344.
Cocrystal Pharma Q3 2026 Earnings: Key Takeaways
Cocrystal Pharma reported a third quarter 2026 net loss of USD 3.44 million and a loss per share of USD 0.20. Cash was USD 4.87 million at September 30, 2026.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...